Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie

In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of late-stage studies testing its would-be oral rival Litfulo in nonsegmenta | In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of late-stage studies testing its would-be oral rival Litfulo in nonsegmental vitiligo.